• Mr. Krushna B. Moin
• Mr. Rahul S. Mohan
• Dr. Rajendra M. Kawde
• Mr. Mahadeo G. Dhote
• Mr. Krishna U. Jagtap

Proton pump inhibitors (PPIs) have emerged as cornerstone therapeutic agents in the management of peptic ulcer and gastroesophageal reflux disease (GERD). This abstract provides a concise overview of the current status of PPIs in the treatment of these gastrointestinal disorders. Peptic ulcers, characterized by mucosal erosions in the stomach or duodenum, are commonly associated with Helicobacter pylori infection or nonsteroidal anti-inflammatory drug (NSAID) use. PPIs exert their therapeutic effects by inhibiting the gastric proton pump, thereby reducing acid secretion and promoting ulcer healing. The efficacy of PPIs in peptic ulcer treatment has been well-established through numerous clinical trials. In GERD, a chronic condition marked by the reflux of stomach acid into the esophagus, PPIs are employed to alleviate symptoms and prevent complications such as esophagitis and Barrett's esophagus. PPIs act by suppressing gastric acid production, promoting esophageal healing, and mitigating symptoms such as heartburn and regurgitation. Long-term use of PPIs in GERD is a subject of ongoing research, considering potential side effects and the risk of rebound acid hypersecretion upon discontinuation. While PPIs have demonstrated efficacy and safety in the short-term management of peptic ulcers and GERD, ongoing research explores their optimal duration of use, potential adverse effects, and the role of alternative treatment modalities. Additionally, individual patient characteristics and preferences should be considered when determining the most suitable therapeutic approach. In conclusion, proton pump inhibitors remain integral in the contemporary management of peptic ulcer and GERD, offering effective acid suppression and promoting mucosal healing. However, ongoing research is essential to refine treatment strategies, address long-term concerns, and explore alternative options for patients with specific needs or contraindications.

1. Proton pump inhibitors 2. Treatment 3. Peptic ulcer 4. Gastroesophageal reflux disease (GERD) 5. Update

"An Update On Proton pump inhibitors in the treatment of peptic ulcer and gastroesophageal reflux disease", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 11, page no.d355-d363, November-2023, Available :http://www.jetir.org/papers/JETIR2311348.pdf

"An Update On Proton pump inhibitors in the treatment of peptic ulcer and gastroesophageal reflux disease", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 11, page no. ppd355-d363, November-2023, Available at : http://www.jetir.org/papers/JETIR2311348.pdf